typhoid polysaccharide vaccine (Rx)

Brand and Other Names:Typhim Vi
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection solution

  • 25 mcg derived from S. typhi Ty2 strain/0.5 mL
more...

Typhoid Fever Prophylaxis

Indicated for selective immunization against typhoid fever for people traveling to endemic areas

0.5 mL IM once 2 weeks prior to expected exposure

Booster: 0.5 mL IM q2years

Dosing Considerations

Current vaccination schedules available at http://www.cdc.gov/vaccines/default.htm

Dosage Forms & Strengths

injection solution

  • 25 mcg derived from S. typhi Ty2 strain/0.5 mL
more...

Typhoid Fever Prophylaxis

Indicated for selective immunization against typhoid fever for people traveling to endemic areas

<2 years: Safety and efficacy not established

≥2 years: 0.5 mL IM once 2 weeks prior to expected exposure

Booster: 0.5 mL IM q2years

Dosing Considerations

Current vaccination schedules available at http://www.cdc.gov/vaccines/default.htm

Next:

Interactions

Interaction Checker

and typhoid polysaccharide vaccine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            >10%

            Fever (2-32%)

            Malaise (4-24%)

            Headache (16-20%)

            Soreness (16%)

            Induration (5-15%)

            General aches (1-13%)

            1-10%

            Abdominal pain (6.4%)

            Nausea (<8%)

            Diarrhea (2.9%)

            Vomiting (1.5%)

            Skin rash (1%)

            Pruritus (<8%)

            Myalgia (3-7%)

            <1%

            Cervical pain

            Diarrhea

            Flu-like syndrome

            Arthralgia

            Abdominal pain

            Loss of consciousness

            Perforated jejunum

            Weakness

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            Complete vaccination 1wk before exposure (endemic areas = Africa, Asia, Central & S. America)

            Efficacy: oral 60-70%, parenteral 70-96%

            Efficacy: oral 60-70%; parenteral 70-96%

            May administer Hib, DTP, OPV, IPV, MMR, influenza, and hepatitis B vaccines at same time

            Syncope accompanied by transient visual disturbances reported with injectable vaccines

            Not for the treatment of typhoid fever

            Not all vaccine recipients become protected against typhoid fever; take the ncessary precautions to ingest food or water that may be contaminated

            Administer at least 2 weeks prior to expected exposure

            Avoid administration in patients with moderate or severe acute illness

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Not known if excreted in breast ; use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Live attenuateTY21a strain lacks enzyme UDP-4-galactose epimerase, which causes lipopolysaccharide to be synthesized under conditions that induce bacterial autolys; the avirulent strain produces enough lipopolysaccharide to evoke a protective immune response

            Conveys active immunity via stimulation of production of endogenously produced antibodies

            Pharmacokinetics

            Duration: 17-21 months

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous